Paranoid schizophrenia

Summary

Paranoid schizophrenia (MONDO:0001484) is a disease and 3 clinical trials. Top therapeutic interventions include mk-0557 and mk-0249. A subtype of schizophrenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paranoid schizophrenia
Mondo ID	MONDO:0001484
MeSH	D012563
DOID	DOID:1229
ICD-10-CM	F20.0
NCIT	C35006
SNOMED CT	31658008
UMLS	C0036349
MedGen	20664
Is cancer (heuristic)	no

Also known as: paranoid type schizophrenia · paraphrenic schizophrenia

Disease family

This is a subtype of schizophrenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › psychotic disorder › schizophrenia › paranoid schizophrenia

Related subtypes (17): treatment-refractory schizophrenia, schizophrenia 1, schizophrenia 3, schizophrenia 5, schizophrenia 7, schizophrenia 8, schizophrenia 2, schizophrenia 10, schizophrenia 11, schizophrenia 12, schizophrenia 15, schizophrenia 16, chromosome 2p16.3 deletion syndrome, early-onset schizophrenia, schizophrenia 19, schizophrenia 17, childhood-onset schizophrenia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00482430	PHASE2	COMPLETED	MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
NCT00506077	PHASE2	COMPLETED	MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
NCT04902066	Not specified	COMPLETED	Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for Paranoia.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MK-0557	3	1
MK-0249	2	1